<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04860000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P21802</UniProt_ID>
  <Seq_Length>821</Seq_Length>
  <Molecule_Weight>92025</Molecule_Weight>
  <KEGG_ID>hsa:2263</KEGG_ID>
  <Orthology_ID>K05093</Orthology_ID>
  <EBI_ID>EBI-1028658</EBI_ID>
  <Function_Summary>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and imature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF07679:I-set@@PF07714:Pkinase_Tyr</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>K-sam</Alias>
      <Alias>KGFR</Alias>
      <Alias>FGFR-2</Alias>
      <Alias>Keratinocyte growth factor receptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heparin, any member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha1-4-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.</Detail>
      <Keyword>Heparin binding</Keyword>
      <Ontology_ID>GO:0008201</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with fibroblast growth factor.</Detail>
      <Keyword>Fibroblast growth factor binding</Keyword>
      <Ontology_ID>GO:0017134</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with fibroblast growth factor to initiate a change in cell activity.</Detail>
      <Keyword>Fibroblast growth factor receptor activity</Keyword>
      <Ontology_ID>GO:0005007</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>628</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>288</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>526</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>290</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>362</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>278</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>292</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>281</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>384</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>328</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>289</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>659</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>263</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>186</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>340</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>372</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>375</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>331</Position>
      <Original>Asn</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>344</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>272</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>105</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>340</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>267</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>549</Position>
      <Original>Asn</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>341</Position>
      <Original>Thr</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>315</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>314</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Ser</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>344</Position>
      <Original>Ala</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>347</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>57</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>612</Position>
      <Original>Arg</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>678</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>290</Position>
      <Original>Trp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>641</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>648</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>359</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>203</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>565</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>172</Position>
      <Original>Ala</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>321</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>663</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>301</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>6</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>351</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Ser</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>278</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>276</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>283</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>613</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>290</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>337</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>253</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cell fate commitment. Cell fate commitment is the commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.</Detail>
      <Keyword>Regulation of cell fate commitment</Keyword>
      <Ontology_ID>GO:0010453</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell of the lung. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.</Detail>
      <Keyword>Mesenchymal cell differentiation involved in lung development</Keyword>
      <Ontology_ID>GO:0060915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate or frequency of epithelial cell proliferation that results in the lung attaining its shape.</Detail>
      <Keyword>Positive regulation of epithelial cell proliferation involved in lung morphogenesis</Keyword>
      <Ontology_ID>GO:0060501</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of the hair follicle are generated and organized.</Detail>
      <Keyword>Hair follicle morphogenesis</Keyword>
      <Ontology_ID>GO:0031069</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of smoothened signaling.</Detail>
      <Keyword>Regulation of smoothened signaling pathway</Keyword>
      <Ontology_ID>GO:0008589</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell division.</Detail>
      <Keyword>Positive regulation of cell division</Keyword>
      <Ontology_ID>GO:0051781</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor-type receptor binding to one of its physiological ligands, which contributes to the progression of the orbitofrontal cortex over time from its initial formation until its mature state.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development</Keyword>
      <Ontology_ID>GO:0035607</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of progression through the cell cycle.</Detail>
      <Keyword>Positive regulation of cell cycle</Keyword>
      <Ontology_ID>GO:0045787</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the lacrimal gland over time, from its formation to the mature structure. The lacrimal gland produces secretions that lubricate and protect the cornea of the eye.</Detail>
      <Keyword>Lacrimal gland development</Keyword>
      <Ontology_ID>GO:0032808</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the membranous septum is generated and organized. The membranous septum is the upper part of ventricular septum.</Detail>
      <Keyword>Membranous septum morphogenesis</Keyword>
      <Ontology_ID>GO:0003149</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Generation of a long process of a neuron, that carries efferent (outgoing) action potentials from the cell body towards target cells.</Detail>
      <Keyword>Axonogenesis</Keyword>
      <Ontology_ID>GO:0007409</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that mediates the transfer of information from one cell to another.</Detail>
      <Keyword>Cell-cell signaling</Keyword>
      <Ontology_ID>GO:0007267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.</Detail>
      <Keyword>Positive regulation of ERK1 and ERK2 cascade</Keyword>
      <Ontology_ID>GO:0070374</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The developmental growth process in which solid chords of prostate epithelium increase in length.</Detail>
      <Keyword>Prostate epithelial cord elongation</Keyword>
      <Ontology_ID>GO:0060523</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process pertaining to the initial formation of a limb bud from unspecified parts. This process begins with the formation of a local condensation of mesenchyme cells within the prospective limb field, and ends when a limb bud is recognizable.</Detail>
      <Keyword>Limb bud formation</Keyword>
      <Ontology_ID>GO:0060174</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cardiac muscle cell proliferation.</Detail>
      <Keyword>Positive regulation of cardiac muscle cell proliferation</Keyword>
      <Ontology_ID>GO:0060045</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The increase in size or mass of an organ. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that function together as to perform a specific function.</Detail>
      <Keyword>Organ growth</Keyword>
      <Ontology_ID>GO:0035265</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The branching morphogenesis process in which the prostate epithelial cords branch freely to create the structure of the prostate acini.</Detail>
      <Keyword>Prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis</Keyword>
      <Ontology_ID>GO:0060527</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which stops, prevents, or reduces the frequency, rate or extent of the occurrence or rate of cell death by apoptosis in the bone marrow.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptosis in bone marrow</Keyword>
      <Ontology_ID>GO:0035602</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.</Detail>
      <Keyword>Regulation of fibroblast growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0040036</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which contributes to hemopoiesis.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway involved in hemopoiesis</Keyword>
      <Ontology_ID>GO:0035603</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of a tooth or teeth over time, from formation to the mature structure(s). A tooth is any hard bony, calcareous, or chitinous organ found in the mouth or pharynx of an animal and used in procuring or masticating food.</Detail>
      <Keyword>Odontogenesis</Keyword>
      <Ontology_ID>GO:0042476</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.</Detail>
      <Keyword>Angiogenesis</Keyword>
      <Ontology_ID>GO:0001525</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which activates or increases the frequency, rate or extent of cell proliferation in the bone marrow.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow</Keyword>
      <Ontology_ID>GO:0035604</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized epithelial cell acquires specialized features of a squamous basal epithelial stem cell of the prostate.</Detail>
      <Keyword>Squamous basal epithelial stem cell differentiation involved in prostate gland acinus development</Keyword>
      <Ontology_ID>GO:0060529</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of cardiac ventricle muscle is generated and organized.</Detail>
      <Keyword>Ventricular cardiac muscle tissue morphogenesis</Keyword>
      <Ontology_ID>GO:0055010</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure. See embryonic development.</Detail>
      <Keyword>Post-embryonic development</Keyword>
      <Ontology_ID>GO:0009791</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency, or extent of prostate gland branching, the process in which the branching structure of the prostate gland is generated and organized. A branch is a division or offshoot from a main stem.</Detail>
      <Keyword>Regulation of branching involved in prostate gland morphogenesis</Keyword>
      <Ontology_ID>GO:0060687</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of epithelial cells of the submandibular salivary gland, resulting in the expansion of a cell population and the shaping of the gland.</Detail>
      <Keyword>Epithelial cell proliferation involved in salivary gland morphogenesis</Keyword>
      <Ontology_ID>GO:0060664</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which bones are generated and organized.</Detail>
      <Keyword>Bone morphogenesis</Keyword>
      <Ontology_ID>GO:0060349</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process that results in the patterns of cell differentiation that will arise in an embryo.</Detail>
      <Keyword>Embryonic pattern specification</Keyword>
      <Ontology_ID>GO:0009880</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.</Detail>
      <Keyword>Positive regulation of phospholipase activity</Keyword>
      <Ontology_ID>GO:0010518</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a bud in the lung grows out from the point where it is formed.</Detail>
      <Keyword>Bud elongation involved in lung branching</Keyword>
      <Ontology_ID>GO:0060449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of the digestive tract are generated and organized during embryonic development. The digestive tract is the anatomical structure through which food passes and is processed.</Detail>
      <Keyword>Embryonic digestive tract morphogenesis</Keyword>
      <Ontology_ID>GO:0048557</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of osteoblast differentiation.</Detail>
      <Keyword>Regulation of osteoblast differentiation</Keyword>
      <Ontology_ID>GO:0045667</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the alveolus over time, from its formation to the mature structure. The alveolus is a sac for holding air in the lungs; formed by the terminal dilation of air passageways.</Detail>
      <Keyword>Lung alveolus development</Keyword>
      <Ontology_ID>GO:0048286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The differential growth of the salivary branches along their axis, resulting in the growth of a branch.</Detail>
      <Keyword>Branch elongation involved in salivary gland morphogenesis</Keyword>
      <Ontology_ID>GO:0060667</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of smooth muscle cell differentiation.</Detail>
      <Keyword>Regulation of smooth muscle cell differentiation</Keyword>
      <Ontology_ID>GO:0051150</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of a lung lobe are generated and organized. A lung lobe is a projection that extends from the lung.</Detail>
      <Keyword>Lung lobe morphogenesis</Keyword>
      <Ontology_ID>GO:0060463</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process resulting in the transition of the otic placode into the otic vesicle, a transient embryonic structure formed during development of the vertebrate inner ear.</Detail>
      <Keyword>Otic vesicle formation</Keyword>
      <Ontology_ID>GO:0030916</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of the outflow tract septum are generated and organized. The outflow tract septum is a partition in the outflow tract.</Detail>
      <Keyword>Outflow tract septum morphogenesis</Keyword>
      <Ontology_ID>GO:0003148</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The progression of a pyramidal neuron from its initial formation to its mature state.</Detail>
      <Keyword>Pyramidal neuron development</Keyword>
      <Ontology_ID>GO:0021860</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population that contributes to the progression of the lung over time. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.</Detail>
      <Keyword>Mesenchymal cell proliferation involved in lung development</Keyword>
      <Ontology_ID>GO:0060916</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of branches in a nerve are generated and organized. This term refers to an anatomical structure (nerve) not a cell (neuron).</Detail>
      <Keyword>Branching morphogenesis of a nerve</Keyword>
      <Ontology_ID>GO:0048755</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of the Wnt receptor signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.</Detail>
      <Keyword>Positive regulation of canonical Wnt receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0090263</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of a fibroblast growth factor to its receptor on the surface of al cell in the epidermis resulting in the formation of the mammary line. The mammary line is a ridge of epidermal cells that will form the mammary placodes.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway involved in mammary gland specification</Keyword>
      <Ontology_ID>GO:0060595</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the midbrain over time, from its formation to the mature structure. The midbrain is the middle division of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes a ventral part containing the cerebral peduncles and a dorsal tectum containing the corpora quadrigemina and that surrounds the aqueduct of Sylvius connecting the third and fourth ventricles).</Detail>
      <Keyword>Midbrain development</Keyword>
      <Ontology_ID>GO:0030901</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.</Detail>
      <Keyword>Cell fate commitment</Keyword>
      <Ontology_ID>GO:0045165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of osteoblast proliferation.</Detail>
      <Keyword>Regulation of osteoblast proliferation</Keyword>
      <Ontology_ID>GO:0033688</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The deposition of calcium phosphate in bone tissue.</Detail>
      <Keyword>Bone mineralization</Keyword>
      <Ontology_ID>GO:0030282</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The biological process whose specific outcome is the progression of a lung-associated mesenchyme from an initial condition to its mature state. This process begins with the formation of lung-associated mesenchyme and ends with the mature structure. Lung-associated mesenchyme is the tissue made up of loosely connected mesenchymal cells in the lung.</Detail>
      <Keyword>Lung-associated mesenchyme development</Keyword>
      <Ontology_ID>GO:0060484</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a branch forms along the side of an epithelium.</Detail>
      <Keyword>Lateral sprouting from an epithelium</Keyword>
      <Ontology_ID>GO:0060601</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.</Detail>
      <Keyword>Insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the ureteric bud over time, from its formation to the mature structure.</Detail>
      <Keyword>Ureteric bud development</Keyword>
      <Ontology_ID>GO:0001657</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.</Detail>
      <Keyword>Peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0018108</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The proliferation of neuroblasts in the ventricular zone of the cerebral cortex. The neuronal progenitors of these cells will migrate radially.</Detail>
      <Keyword>Ventricular zone neuroblast division</Keyword>
      <Ontology_ID>GO:0021847</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of growth of the body of an organism so that it reaches its usual body size.</Detail>
      <Keyword>Regulation of multicellular organism growth</Keyword>
      <Ontology_ID>GO:0040014</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The morphogenetic process in which a bud forms from the mammary placode. A mammary bud is bulb of epithelial cells that is distinct from the surrounding epidermis.</Detail>
      <Keyword>Mammary gland bud formation</Keyword>
      <Ontology_ID>GO:0060615</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of activating or increasing the rate or extent of mesenchymal cell proliferation. Mesenchymal cells are loosely organized embryonic cells.</Detail>
      <Keyword>Positive regulation of mesenchymal cell proliferation</Keyword>
      <Ontology_ID>GO:0002053</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The increase in size or mass of an entire multicellular organism, as opposed to cell growth.</Detail>
      <Keyword>Multicellular organism growth</Keyword>
      <Ontology_ID>GO:0035264</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the branches of the fetal placental villi are generated and organized. The villous part of the placenta is called the labyrinth layer.</Detail>
      <Keyword>Branching involved in embryonic placenta morphogenesis</Keyword>
      <Ontology_ID>GO:0060670</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>656</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>586</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>588</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>769</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>448</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>449</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>466</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>657</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT</Protein_Seq>
    <DNA_Seq>GGCGGCGGCTGGAGGAGAGCGCGGTGGAGAGCCGAGCGGGCGGGCGGCGGGTGCGGAGCGGGCGAGGGAGCGCGCGCGGCCGCCACAAAGCTCGGGCGCCGCGGGGCTGCATGCGGCGTACCTGGCCCGGCGCGGCGACTGCTCTCCGGGCTGGCGGGGGCCGGCCGCGAGCCCCGGGGGCCCCGAGGCCGCAGCTTGCCTGCGCGCTCTGAGCCTTCGCAACTCGCGAGCAAAGTTTGGTGGAGGCAACGCCAAGCCTGAGTCCTTTCTTCCTCTCGTTCCCCAAATCCGAGGGCAGCCCGCGGGCGTCATGCCCGCGCTCCTCCGCAGCCTGGGGTACGCGTGAAGCCCGGGAGGCTTGGCGCCGGCGAAGACCCAAGGACCACTCTTCTGCGTTTGGAGTTGCTCCCCGCAACCCCGGGCTCGTCGCTTTCTCCATCCCGACCCACGCGGGGCGCGGGGACAACACAGGTCGCGGAGGAGCGTTGCCATTCAAGTGACTGCAGCAGCAGCGGCAGCGCCTCGGTTCCTGAGCCCACCGCAGGCTGAAGGCATTGCGCGTAGTCCATGCCCGTAGAGGAAGTGTGCAGATGGGATTAACGTCCACATGGAGATATGGAAGAGGACCGGGGATTGGTACCGTAACCATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACGGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCACCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCAGACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAAACATGAATGACTGTGTCTGCCTGTCCCCAAACAGGACAGCACTGGGAACCTAGCTACACTGAGCAGGGAGACCATGCCTCCCAGAGCTTGTTGTCTCCACTTGTATATATGGATCAGAGGAGTAAATAATTGGAAAAGTAATCAGCATATGTGTAAAGATTTATACAGTTGAAAACTTGTAATCTTCCCCAGGAGGAGAAGAAGGTTTCTGGAGCAGTGGACTGCCACAAGCCACCATGTAACCCCTCTCACCTGCCGTGCGTACTGGCTGTGGACCAGTAGGACTCAAGGTGGACGTGCGTTCTGCCTTCCTTGTTAATTTTGTAATAATTGGAGAAGATTTATGTCAGCACACACTTACAGAGCACAAATGCAGTATATAGGTGCTGGATGTATGTAAATATATTCAAATTATGTATAAATATATATTATATATTTACAAGGAGTTATTTTTTGTATTGATTTTAAATGGATGTCCCAATGCACCTAGAAAATTGGTCTCTCTTTTTTTAATAGCTATTTGCTAAATGCTGTTCTTACACATAATTTCTTAATTTTCACCGAGCAGAGGTGGAAAAATACTTTTGCTTTCAGGGAAAATGGTATAACGTTAATTTATTAATAAATTGGTAATATACAAAACAATTAATCATTTATAGTTTTTTTTGTAATTTAAGTGGCATTTCTATGCAGGCAGCACAGCAGACTAGTTAATCTATTGCTTGGACTTAACTAGTTATCAGATCCTTTGAAAAGAGAATATTTACAATATATGACTAATTTGGGGAAAATGAAGTTTTGATTTATTTGTGTTTAAATGCTGCTGTCAGACGATTGTTCTTAGACCTCCTAAATGCCCCATATTAAAAGAACTCATTCATAGGAAGGTGTTTCATTTTGGTGTGCAACCCTGTCATTACGTCAACGCAACGTCTAACTGGACTTCCCAAGATAAATGGTACCAGCGTCCTCTTAAAAGATGCCTTAATCCATTCCTTGAGGACAGACCTTAGTTGAAATGATAGCAGAATGTGCTTCTCTCTGGCAGCTGGCCTTCTGCTTCTGAGTTGCACATTAATCAGATTAGCCTGTATTCTCTTCAGTGAATTTTGATAATGGCTTCCAGACTCTTTGGCGTTGGAGACGCCTGTTAGGATCTTCAAGTCCCATCATAGAAAATTGAAACACAGAGTTGTTCTGCTGATAGTTTTGGGGATACGTCCATCTTTTTAAGGGATTGCTTTCATCTAATTCTGGCAGGACCTCACCAAAAGATCCAGCCTCATACCTACATCAGACAAAATATCGCCGTTGTTCCTTCTGTACTAAAGTATTGTGTTTTGCTTTGGAAACACCCACTCACTTTGCAATAGCCGTGCAAGATGAATGCAGATTACACTGATCTTATGTGTTACAAAATTGGAGAAAGTATTTAATAAAACCTGTTAATTTTTATACTGACAATAAAAATGTTTCTACAGATATTAATGTTAACAAGACAAAATAAATGTCACGCAACTTATTTTTTTAATAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell cortex</CellLocal>
      <Ontology_ID>GO:0005938</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Golgi apparatus</CellLocal>
      <Ontology_ID>GO:0005794</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasmic membrane-bounded vesicle</CellLocal>
      <Ontology_ID>GO:0016023</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell surface</CellLocal>
      <Ontology_ID>GO:0009986</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Excitatory synapse</CellLocal>
      <Ontology_ID>GO:0060076</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasmic vesicle</CellLocal>
      <Ontology_ID>GO:0031410</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to plasma membrane</CellLocal>
      <Ontology_ID>GO:0005887</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>FGFR2</Gene_Name>
    <Gene_Alias>BEK; KGFR; KSAM</Gene_Alias>
    <Gene_ID>2263</Gene_ID>
    <Genbank_ACCN>NM_000141</Genbank_ACCN>
    <Protein_ACCN>NP_000132</Protein_ACCN>
    <HGNC_ID>3689</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2263</Gene_URL>
    <UCSC_ID>uc021qaa.1</UCSC_ID>
    <EMBL_ID>ENSG00000066468</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P05230</Uniprot_ID>
      <Gene_Name>FGF1</Gene_Name>
      <EBI_ID>EBI-698068</EBI_ID>
      <PPI_EBI_URL>EBI-1028658,EBI-698068</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P09038</Uniprot_ID>
      <Gene_Name>FGF2</Gene_Name>
      <EBI_ID>EBI-977447</EBI_ID>
      <PPI_EBI_URL>EBI-1028658,EBI-977447</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Gastric Cancer, Somatic</Disease_Name>
      <Disease_Detail>Gastric Cancer</Disease_Detail>
      <Disease_DB>GST060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_cancer_somatic?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Wells Syndrome</Disease_Name>
      <Disease_Detail>Wells Syndrome</Disease_Detail>
      <Disease_DB>WLL006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/wells_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Cancer</Disease_Name>
      <Disease_Detail>Gastric Cancer</Disease_Detail>
      <Disease_DB>GST053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_cancer?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Crouzon Syndrome</Disease_Name>
      <Disease_Detail>Crouzon Syndrome</Disease_Detail>
      <Disease_DB>CRZ001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/crouzon_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Synostosis</Disease_Name>
      <Disease_Detail>Synostosis</Disease_Detail>
      <Disease_DB>SYN005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/synostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Carcinoma, Somatic</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_carcinoma_somatic?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypochondroplasia</Disease_Name>
      <Disease_Detail>Hypochondroplasia</Disease_Detail>
      <Disease_DB>HYP042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypochondroplasia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Muenke Syndrome</Disease_Name>
      <Disease_Detail>Muenke Syndrome</Disease_Detail>
      <Disease_DB>MNK003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/muenke_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acanthosis Nigricans</Disease_Name>
      <Disease_Detail>Acanthosis Nigricans</Disease_Detail>
      <Disease_DB>ACN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acanthosis_nigricans?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr2-Related Craniosynostosis</Disease_Name>
      <Disease_Detail>Fgfr2-Related Craniosynostosis</Disease_Detail>
      <Disease_DB>FGF004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr2_related_craniosynostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antley-Bixler Syndrome Without Genital Anomalies or Disordered Steroidogenesis</Disease_Name>
      <Disease_Detail>Antley-Bixler Syndrome</Disease_Detail>
      <Disease_DB>ANT057</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antley_bixler_syndrome_without_genital_anomalies_or_disordered_steroidogenesis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Infectious Mononucleosis</Disease_Name>
      <Disease_Detail>Infectious Mononucleosis</Disease_Detail>
      <Disease_DB>INF030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/infectious_mononucleosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Stomach Cancer, Childhood</Disease_Name>
      <Disease_Detail>Stomach Cancer</Disease_Detail>
      <Disease_DB>STM011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/stomach_cancer_childhood?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr2-Related Isolated Coronal Synostosis</Disease_Name>
      <Disease_Detail>Fgfr2-Related Isolated Coronal Synostosis</Disease_Detail>
      <Disease_DB>FGF005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr2_related_isolated_coronal_synostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Syringomyelia</Disease_Name>
      <Disease_Detail>Syringomyelia</Disease_Detail>
      <Disease_DB>SYR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/syringomyelia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer Susceptibility</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS081</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_susceptibility?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Beare-Stevenson Cutis Gyrata Syndrome</Disease_Name>
      <Disease_Detail>Beare-Stevenson Cutis Gyrata Syndrome</Disease_Detail>
      <Disease_DB>BRS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/beare_stevenson_cutis_gyrata_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Carcinoma</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_carcinoma?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acrocephalosyndactylia</Disease_Name>
      <Disease_Detail>Acrocephalosyndactylia</Disease_Detail>
      <Disease_DB>ACR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acrocephalosyndactylia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Radioulnar Synostosis</Disease_Name>
      <Disease_Detail>Radioulnar Synostosis</Disease_Detail>
      <Disease_DB>RDL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/radioulnar_synostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Clear Cell Acanthoma</Disease_Name>
      <Disease_Detail>Clear Cell Acanthoma</Disease_Detail>
      <Disease_DB>CLR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/clear_cell_acanthoma?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thanatophoric Dysplasia Type 1</Disease_Name>
      <Disease_Detail>Thanatophoric Dysplasia</Disease_Detail>
      <Disease_DB>THN004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thanatophoric_dysplasia_type_1?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome Type 3</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome_type_3?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Craniosynostosis</Disease_Name>
      <Disease_Detail>Craniosynostosis</Disease_Detail>
      <Disease_DB>CRN037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/craniosynostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antley-Bixler Syndrome</Disease_Name>
      <Disease_Detail>Antley-Bixler Syndrome</Disease_Detail>
      <Disease_DB>ANT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antley_bixler_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiocranial Syndrome</Disease_Name>
      <Disease_Detail>Cardiocranial Syndrome</Disease_Detail>
      <Disease_DB>CRD019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiocranial_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ladd Syndrome</Disease_Name>
      <Disease_Detail>Ladd Syndrome</Disease_Detail>
      <Disease_DB>LDD001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ladd_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Humeroradial Synostosis</Disease_Name>
      <Disease_Detail>Humeroradial Synostosis</Disease_Detail>
      <Disease_DB>HMR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/humeroradial_synostosis?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Saethre-Chotzen Syndrome with Eyelid Anomalies</Disease_Name>
      <Disease_Detail>Saethre-Chotzen Syndrome</Disease_Detail>
      <Disease_DB>STH002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/saethre_chotzen_syndrome_with_eyelid_anomalies?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Saethre-Chotzen Syndrome, Fgfr2-Related</Disease_Name>
      <Disease_Detail>Saethre-Chotzen Syndrome</Disease_Detail>
      <Disease_DB>STH004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/saethre_chotzen_syndrome_fgfr2_related?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Stomach Cancer, Familial</Disease_Name>
      <Disease_Detail>Stomach Cancer</Disease_Detail>
      <Disease_DB>STM012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/stomach_cancer_familial?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome Type 1</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome_type_1?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Crouzonodermoskeletal Syndrome</Disease_Name>
      <Disease_Detail>Crouzonodermoskeletal Syndrome</Disease_Detail>
      <Disease_DB>CRZ003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/crouzonodermoskeletal_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome Type 1, 2 and 3</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome_type_1_2_and_3?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Craniosynostosis, Nonspecific</Disease_Name>
      <Disease_Detail>Craniosynostosis</Disease_Detail>
      <Disease_DB>CRN118</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/craniosynostosis_nonspecific?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr2-Related Lacrimo-Auriculo-Dento-Digital Syndrome</Disease_Name>
      <Disease_Detail>Fgfr2-Related Lacrimo-Auriculo-Dento-Digital Syndrome</Disease_Detail>
      <Disease_DB>FGF006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr2_related_lacrimo_auriculo_dento_digital_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Cancer, Familial</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END056</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_cancer_familial?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thanatophoric Dysplasia</Disease_Name>
      <Disease_Detail>Thanatophoric Dysplasia</Disease_Detail>
      <Disease_DB>THN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thanatophoric_dysplasia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bent Bone Dysplasia Syndrome</Disease_Name>
      <Disease_Detail>Bent Bone Dysplasia Syndrome</Disease_Detail>
      <Disease_DB>BNT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bent_bone_dysplasia_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Saethre-Chotzen Syndrome</Disease_Name>
      <Disease_Detail>Saethre-Chotzen Syndrome</Disease_Detail>
      <Disease_DB>STH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/saethre_chotzen_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr-Related Craniosynostosis Syndromes</Disease_Name>
      <Disease_Detail>Fgfr-Related Craniosynostosis Syndromes</Disease_Detail>
      <Disease_DB>FGF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr_related_craniosynostosis_syndromes?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gliomatosis Cerebri</Disease_Name>
      <Disease_Detail>Gliomatosis Cerebri</Disease_Detail>
      <Disease_DB>GLM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliomatosis_cerebri?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Exophthalmos</Disease_Name>
      <Disease_Detail>Exophthalmos</Disease_Detail>
      <Disease_DB>EXP004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/exophthalmos?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scaphocephaly and Axenfeld-Rieger Anomaly</Disease_Name>
      <Disease_Detail>Scaphocephaly and Axenfeld-Rieger Anomaly</Disease_Detail>
      <Disease_DB>SCP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scaphocephaly_and_axenfeld_rieger_anomaly?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Stomach Cancer</Disease_Name>
      <Disease_Detail>Stomach Cancer</Disease_Detail>
      <Disease_DB>STM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/stomach_cancer?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acanthoma</Disease_Name>
      <Disease_Detail>Acanthoma</Disease_Detail>
      <Disease_DB>ACN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acanthoma?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scaphocephaly, Maxillary Retrusion, and Mental Retardation</Disease_Name>
      <Disease_Detail>Scaphocephaly, Maxillary Retrusion, and Mental Retardation</Disease_Detail>
      <Disease_DB>SCP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scaphocephaly_maxillary_retrusion_and_mental_retardation?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Plagiocephaly</Disease_Name>
      <Disease_Detail>Plagiocephaly</Disease_Detail>
      <Disease_DB>PLG004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/plagiocephaly?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoglophonic Dysplasia</Disease_Name>
      <Disease_Detail>Osteoglophonic Dysplasia</Disease_Detail>
      <Disease_DB>OST044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoglophonic_dysplasia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cytochrome P450 Oxidoreductase Deficiency</Disease_Name>
      <Disease_Detail>Cytochrome P450 Oxidoreductase Deficiency</Disease_Detail>
      <Disease_DB>CYT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cytochrome_p450_oxidoreductase_deficiency?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Jackson-Weiss Syndrome</Disease_Name>
      <Disease_Detail>Jackson-Weiss Syndrome</Disease_Detail>
      <Disease_DB>JCK001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/jackson_weiss_syndrome?search=FGFR2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Achondroplasia</Disease_Name>
      <Disease_Detail>Achondroplasia</Disease_Detail>
      <Disease_DB>ACH004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/achondroplasia?search=FGFR2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX</PDB_Title>
      <PDB_ID>1E0O</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E0O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Fibroblast Growth Factor Receptor Ectodomain Bound to Ligand and Heparin</PubMed_Title>
      <Author>Pellegrini, L., et al.</Author>
      <Journal>Nature(2000)407:1029-1034</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11069186?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of 2:2:2 FGFR2D2:FGF1:SOS complex</PDB_Title>
      <PDB_ID>3CU1</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CU1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of 2:2:2 FGFR2D2:FGF1:SOS complex</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of FGF1 complexed with the ectodomain of FGFR2b harboring P253R Apert mutation</PDB_Title>
      <PDB_ID>3OJM</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OJM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1.</PubMed_Title>
      <Author>Beenken, A., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:3067-3078</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22057274?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of the D2 Domain of the Fibroblast Growth Factor</PDB_Title>
      <PDB_ID>1WVZ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WVZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the D2 Domain of the Fibroblast Growth Factor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome</PDB_Title>
      <PDB_ID>2PY3</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PY3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K641R Mutation Responsible for Pfeiffer Syndrome</PDB_Title>
      <PDB_ID>2PZR</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PZR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of hFGFR2 D2 Domain</PDB_Title>
      <PDB_ID>3CAF</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CAF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure analysis of the hFGFR2 D2 domain</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K526E Mutation Responsible for Crouzon Syndrome</PDB_Title>
      <PDB_ID>2PZP</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PZP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565A Mutation Responsible for Pfeiffer Syndrome</PDB_Title>
      <PDB_ID>2Q0B</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q0B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Fibroblast growth factor (FGF)8b in complex with FGF Receptor (FGFR) 2c</PDB_Title>
      <PDB_ID>2FDB</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FDB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain</PubMed_Title>
      <Author>Olsen, S.K., et al.</Author>
      <Journal>Genes Dev.(2006)20:185-198</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16384934?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FGFR2 KINASE DOMAIN</PDB_Title>
      <PDB_ID>1OEC</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OEC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Crystal Structure of the Fgfr2 Tyrosine Kinase Domain in Complex with 4-Aryl-2-Phenylamino Pyrimidine Angiogenesis Inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of D2 domain from human FGFR2</PDB_Title>
      <PDB_ID>3DAR</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DAR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the FGFR2 D2 domain</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069</PDB_Title>
      <PDB_ID>3RI1</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RI1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.</PubMed_Title>
      <Author>Eathiraj, S., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:20677-20687</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21454610?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the FGFR2 D2 domain</PDB_Title>
      <PDB_ID>3EUU</PDB_ID>
      <Resolution>2.34</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EUU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the D2 domain of hFGFR2</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2</PDB_Title>
      <PDB_ID>1II4</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1II4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.</PubMed_Title>
      <Author>Ibrahimi, O.A., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2001)98:7182-7187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11390973?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction</PDB_Title>
      <PDB_ID>3CLY</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CLY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A crystallographic snapshot of tyrosine trans-phosphorylation in action</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2008)105:19660-19665</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19060208?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE FGFR2 TYROSINE KINASE DOMAIN</PDB_Title>
      <PDB_ID>1GJO</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GJO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Fgfr2 Tyrosine Kinase Domain</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation</PDB_Title>
      <PDB_ID>3OJ2</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OJ2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1.</PubMed_Title>
      <Author>Beenken, A., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:3067-3078</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22057274?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome</PDB_Title>
      <PDB_ID>2PZ5</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PZ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Unphosphorylated Unactivated Wild Type FGF Receptor 2 (FGFR2) Kinase Domain</PDB_Title>
      <PDB_ID>2PSQ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PSQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of the FGF10-FGFR2b Complex</PDB_Title>
      <PDB_ID>1NUN</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NUN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis by which alternative splicing confers   specificity in fibroblast growth factor receptors.</PubMed_Title>
      <Author>Yeh, B.K., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2003)100:2266-2271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12591959?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome.</PDB_Title>
      <PDB_ID>2PVY</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PVY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2)</PDB_Title>
      <PDB_ID>1EV2</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EV2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.</PubMed_Title>
      <Author>Plotnikov, A.N., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(2000)101:413-424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10830168?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549H Mutation Responsible for Crouzon Syndrome.</PDB_Title>
      <PDB_ID>2PWL</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PWL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of phosphotransferase</PDB_Title>
      <PDB_ID>3B2T</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B2T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.</PubMed_Title>
      <Author>Lew, E.D., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:19802-19807</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18056630?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide</PDB_Title>
      <PDB_ID>2PVF</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PVF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.</PubMed_Title>
      <Author>Chen, H., et al.</Author>
      <Journal>Mol.Cell(2007)27:717-730</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17803937?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1</PDB_Title>
      <PDB_ID>1DJS</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DJS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural interactions of fibroblast growth factor receptor with its ligands.</PubMed_Title>
      <Author>Stauber, D.J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2000)97:49-54</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10618369?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2</PDB_Title>
      <PDB_ID>1IIL</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IIL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.</PubMed_Title>
      <Author>Ibrahimi, O.A., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2001)98:7182-7187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11390973?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04550</Pathway_ID>
      <Pathway_Title>Signaling pathways regulating pluripotency of stem cells</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04010</Pathway_ID>
      <Pathway_Title>MAPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.b.b.e.bf.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1djs</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Autoinhibition model</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04860001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04878001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>